Yersinia Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: March 16, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.2 billion |
|
Revenue Forecast in 2031 |
US$ 4.63 billion |
|
CAGR |
4.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Test, Technique, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global yersinia diagnostics market was valued at US$ 3.2 billion in 2022 and is expected to register a revenue CAGR of 4.2% to reach US$ 4.63 billion by 2031.
Yersinia Diagnostics Market Fundamentals
Yersinia is a genus of gram-negative bacteria that can cause various diseases in humans and animals. The three main Yersinia species known to cause disease in humans are Yersinia pestis, Yersinia enterocolitica, and Yersinia pseudotuberculosis. Yersinia pestis is responsible for causing the plague, a severe and often fatal disease that has caused epidemics throughout history. Yersinia enterocolitica and Yersinia pseudotuberculosis can cause gastrointestinal infections that may result in diarrhea, abdominal pain, and fever. Various diagnostic tests are available for Yersinia infections, including growing Yersinia bacteria in culture media and identifying them using biochemical tests. Blood tests can be used to detect antibodies to Yersinia bacteria. This can help diagnose past infections or in confirming a suspected diagnosis. Polymerase chain reaction (PCR) can detect the genetic material of Yersinia bacteria in samples, such as blood, stool, or tissue. Imaging studies, such as X-rays or CT scans, may help diagnose conditions, including pneumonic plague. Enzyme-linked immunosorbent assay (ELISA) is a type of blood test that detect specific antibodies to Yersinia bacteria. Immunofluorescence tests use antibodies labeled with fluorescent dyes to detect Yersinia bacteria in tissue samples. The choice of diagnostic test will depend on the patient's specific symptoms and suspected diagnosis.
[755675]
Yersinia Diagnostics Market Dynamics
The global Yersinia diagnostics market is expected to experience moderate revenue growth in the coming years. There are several drivers that are contributing to the revenue growth of the global Yersinia diagnostics market. The incidence of yersiniosis has been increasing in recent years, driving demand for Yersinia diagnostics. According to the Centers for Disease Control and Prevention (CDC), Y. enterocolitica causes almost 117,000 illnesses, 640 hospitalizations, and 35 deaths annually in the United States. The development of new diagnostic technologies, such as PCR and ELISA, has improved the accuracy and speed of Yersinia diagnostics. This has also increased the demand for Yersinia diagnostics products and services. Governments worldwide are investing in various programs to control the spread of infectious diseases, including yersiniosis. This has created a favorable environment for the growth of the Yersinia diagnostics market. Healthcare professionals are becoming more aware of the importance of early and accurate diagnosis of Yersinia infections. This is driving demand for Yersinia diagnostics products and services. Point-of-care testing (POCT) is becoming increasingly popular, allowing for rapid diagnosis and treatment of infectious diseases.
However, the market may face restraints that could impact its growth and development. The cost of Yersinia diagnostics tests is quite high, which may make it difficult for some healthcare facilities or individuals to afford them. Many individuals may not be aware of Yersinia infections and the importance of early detection and treatment. This lack of awareness could lead to lower demand for Yersinia diagnostics tests and slower market revenue growth.
Yersinia Diagnostics Market Ecosystem
The global Yersinia diagnostics market has been analyzed from three perspectives: test, technique, and region.
Yersinia Diagnostics Market by Test
[85444]
Based on test, the global Yersinia diagnostics market has been segmented into ELISA, stool cultures, radioimmunoassay, CT scan, colonoscopy, and ultrasonography.
The stool culture segment accounts for the largest revenue share in the global Yersinia diagnostics market. Stool culture Yersinia diagnostics is a test that uses feces samples to culture the bacteria and obtains a diagnosis. The simplest way to find out is to use the stool culture. The test can be completed in 24 to 48 hours, depending on the lab technique employed, and results are typically available in less than 72 hours. Compared to other serological approaches, stool culture Yersinia diagnostics detects more than 90% of cases (such as ELISA or tube agglutination). This means stool culture is especially helpful in cases where an infection has occurred far from a microbiology facility where these fast antibody testing techniques can be used.
The ELISA segment accounted for the second-largest revenue share in the global Yersinia diagnostics market. An enzyme-linked antibody reaction called an ELISA involves a sample and a chemical that is being studied. The measurement of antigen concentration in solution is the goal of this test. Antibodies in the blood can be found using the ELISA lab test. Detecting these antibodies can suggest infection with the Yersinia bacterium. Nevertheless, as ELISA tests cannot identify living organisms, they are unable to tell if a patient has only recently become ill or has had this kind of illness for some time.
Yersinia Diagnostics Market by Technique
Based on technique, the global Yersinia diagnostics market has been segmented into DNA probes, PCR, immunoassay, monoclonal antibodies, and others.
The PCR segment accounts for the largest revenue share in the global Yersinia diagnostics market. PCR is a powerful molecular technique to detect and identify Yersinia species in clinical and environmental samples. Yersinia is a genus of gram-negative bacteria that can cause a range of diseases, including bubonic plague, enterocolitis, and sepsis. PCR can be used to amplify specific DNA sequences that are unique to Yersinia species, allowing for their rapid detection and identification. One commonly targeted sequence in Yersinia diagnostics is the 16S ribosomal RNA gene, which is highly conserved among bacteria and can be used to distinguish between different bacterial species. In addition to detecting Yersinia in clinical samples, PCR can identify virulence factors associated with pathogenicity, such as the Yersinia virulence plasmid and the Yersinia outer membrane proteins.
The monoclonal antibodies segment is projected to record a high revenue CAGR in the global Yersinia diagnostics market. Monoclonal antibodies can be used in the diagnosis of Yersinia infections. Yersinia is a genus of gram-negative bacteria that includes Yersinia pestis, the causative agent of plague, and Yersinia enterocolitica, which can cause gastrointestinal disease. One application of monoclonal antibodies in Yersinia diagnostics is in the development of immunoassays for detecting the presence of Yersinia antigens or antibodies in patient samples. For instance, monoclonal antibodies can be used in ELISAs to detect Yersinia-specific antigens or antibodies in serum, plasma, or other clinical samples. These assays can provide rapid and accurate diagnoses of Yersinia infections, allowing for early treatment and better patient outcomes.
Yersinia Diagnostics Market by Region
Based on region, the global Yersinia diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest revenue share in the global Yersinia diagnostics market. This is attributed to the well-established healthcare infrastructure, sophisticated diagnostics, etc. The United States accounts for the largest revenue share in the regional market. The Yersinia diagnostics market in the United States is primarily driven by the increasing prevalence of Yersinia infections, which can cause a range of diseases, including Yersiniosis, plague, and gastroenteritis. The market is expected to continue growing due to the rising demand for accurate and rapid diagnostic tests for Yersinia infections. In the United States, infections causing gastroenteritis are the second most common infection. The major players in the Yersinia diagnostics market in the United States include Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., and QIAGEN N.V. These companies offer a range of diagnostic products, including immunoassays, PCR kits, and microbial identification systems for the detection of Yersinia infections. In addition to these established players, a growing number of smaller companies and startups are focused on developing innovative Yersinia diagnostic technologies, such as rapid point-of-care tests and next-generation sequencing platforms. Overall, the Yersinia diagnostics market in the United States is expected to continue growing in the coming years, driven by factors such as the need for more accurate and rapid diagnostic tests and ongoing technological advancements in diagnostic testing.
The Yersinia diagnostics market in the Asia Pacific region is expected to experience significant growth over the forecast period. The market is driven by the increasing incidence of yersinia infections, growing awareness about the disease, and rising healthcare expenditure in the region. The market is segmented based on diagnostic methods, including traditional methods and molecular diagnostics. Traditional methods such as culture and serology are widely used in the region, but molecular diagnostics are expected to gain popularity due to their higher accuracy and sensitivity. China and India are expected to be the major contributors to the market revenue growth due to their large population base and increase in healthcare expenditure.
Yersinia Diagnostics Market Competitive Landscape
The prominent players operating in the global yersinia diagnostics market are:
Yersinia Diagnostics Market Strategic Development/s
The global yersinia diagnostics market is expected to grow at a revenue CAGR of 4.2% during the forecast period.
Abbott Laboratories, Bio-Rad Laboratories, GlaxoSmithKline plc, Danaher Corporation, and Merck KGaA are among the key players in the global yersinia diagnostics market.
The ELISA segment accounts for the largest revenue share in the global yersinia diagnostics market.
Asia Pacific is expected to observe the highest revenue growth in the global yersinia diagnostics market during the forecast period.
The global yersinia diagnostics market was valued at US$ 3.2 billion in 2022.
*Insights on financial performance are subject to the availability of information in the public domain